What is Choice Genetics?
Choice Genetics, powered by Groupe Grimaud, operates as a prominent global swine genetics company. It is dedicated to substantial, long-term investment in research and development to meet evolving industry demands. With operations spanning four continents, Choice Genetics supports pork producers by offering superior efficiency, performance, and value through its advanced breeding stock, marketed in over 25 countries. Key products include the CG32 and NAMA parent gilts, and the EBX and P88 terminal sires. The company emphasizes value-driven innovations and unique phenotypic traits to enhance the accuracy of Estimated Breeding Values (EBVs), thereby accelerating genetic advancement in commercial pig production at a pace that outstrips competitors.
How much funding has Choice Genetics raised?
Choice Genetics has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Choice Genetics?
The recent large-scale, late-stage funding indicates Choice Genetics is poised for significant scaling and further global market penetration. This strategic capital infusion is expected to fuel continued investment in cutting-edge research and development, potentially leading to the introduction of new genetic lines and enhanced product offerings. The company's focus on efficiency and value suggests a strategy aimed at solidifying its market leadership and addressing the growing global demand for high-performance pork production. Future developments may include expansion into new geographical markets or strategic partnerships to broaden its reach and technological capabilities.
See full Choice Genetics company page
